Vorsitz: K. Schäfer (Mainz), K. Stark (München)
| (V1797) | Phenotypes of Treatment Resistant Hypertension and their Response to Interventional Renal Denervation | |
| K. Fengler, K.-P. Kresoja, K.-P. Rommel, S. Blazek, S. Rosch, C. Lücke, M. Gutberlet, H. Thiele, P. Lurz (Leipzig) | ||
| Diskussion | ||
| (V1798) | Microplastic particles induce endothelial activation | |
| N. Trippel, A.-K. Vlacil, S. Bänfer, R. Jacob, B. Schieffer, K. Grote (Marburg) | ||
| Diskussion | ||
| (V1799) | The Influence of Rivaroxaban compared to Vitamin K Antagonist treatment upon development of cardiovascular calcification The IRIVASC-Trial | |
| R. Stöhr, N. Marx, A. Schuh, V. Brandenburg (Aachen, Würselen) | ||
| Diskussion | ||
| (V1800) | Protection from immune checkpoint inhibitor-related cardiotoxicity by blockade of tumour necrosis factor alpha | |
| L. Michel, U. Hendgen-Cotta, R. Mincu, I. Helfrich, S. Korste, S. Margraf, D. Schadendorf, T. Rassaf, M. Totzeck (Essen, München) | ||
| Diskussion | ||
| (V1801) | Keynote Lecture: State-of-the-Art: Immune mechanisms in venous and arterial thrombosis |
|
| W. Ruf (Mainz) | ||
| Diskussion |
| 10:00 - 11:30 | Pause - Posterdiskussion |